245 related articles for article (PubMed ID: 30031603)
1. ANGPTL2 deletion inhibits osteoclast generation by modulating NF-κB/MAPKs/Cyclin pathways.
Li WM; Han CL; Liu C; Xing HY; Ding DC
Biochem Biophys Res Commun; 2018 Sep; 503(3):1471-1477. PubMed ID: 30031603
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
4. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
5. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
6. MLN64 deletion suppresses RANKL-induced osteoclastic differentiation and attenuates diabetic osteoporosis in streptozotocin (STZ)-induced mice.
Lei C; Xueming H; Ruihang D
Biochem Biophys Res Commun; 2018 Nov; 505(4):1228-1235. PubMed ID: 30322615
[TBL] [Abstract][Full Text] [Related]
7. Angptl2 deficiency attenuates paraquat (PQ)-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis through NF-κB pathway.
Yang W; Liu W; Yu W; Fei D; Meng X; Yang S; Meng S; Zhao M
Biochem Biophys Res Commun; 2018 Sep; 503(1):94-101. PubMed ID: 29852175
[TBL] [Abstract][Full Text] [Related]
8. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis.
Hsieh TP; Sheu SY; Sun JS; Chen MH
Phytomedicine; 2011 Jan; 18(2-3):176-85. PubMed ID: 20554188
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of RIPK1/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-κB and MAPKs signaling pathways.
Liang S; Nian Z; Shi K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1028-1035. PubMed ID: 32321638
[TBL] [Abstract][Full Text] [Related]
10. Follistatin-like 1 promotes osteoclast formation via RANKL-mediated NF-κB activation and M-CSF-induced precursor proliferation.
Kim HJ; Kang WY; Seong SJ; Kim SY; Lim MS; Yoon YR
Cell Signal; 2016 Sep; 28(9):1137-1144. PubMed ID: 27234130
[TBL] [Abstract][Full Text] [Related]
11. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
[TBL] [Abstract][Full Text] [Related]
13. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
[TBL] [Abstract][Full Text] [Related]
14. Neuromedin B and its receptor silencing suppresses osteoclast generation by modulating precursor proliferation via M-CSF/c-Fms/D-type cyclins.
Yeo CE; Kang WY; Seong SJ; Cho S; Lee HW; Yoon YR; Kim HJ
Exp Cell Res; 2017 Oct; 359(1):112-119. PubMed ID: 28780306
[TBL] [Abstract][Full Text] [Related]
15. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
[TBL] [Abstract][Full Text] [Related]
16. HDAC9 promotes brain ischemic injury by provoking IκBα/NF-κB and MAPKs signaling pathways.
Lu S; Li H; Li K; Fan XD
Biochem Biophys Res Commun; 2018 Sep; 503(3):1322-1329. PubMed ID: 30031609
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
